Zobrazeno 1 - 2
of 2
pro vyhledávání: '"José M. Rodriguez-Valadez"'
Autor:
José M. Rodriguez‐Valadez, Malak Tahsin, Umesh Masharani, Meyeon Park, M. G. Myriam Hunink, Joseph Yeboah, Lihua Li, Ellerie Weber, Asem Berkalieva, Luuk Avezaat, Wendy Max, Kirsten E. Fleischmann, Bart S. Ferket
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 13, Iss 4 (2024)
Background Prior research suggests clinical effects of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) and sodium‐glucose cotransporter‐2 inhibitors (SGLT2is) are mediated by changes in glycated hemoglobin, body weight, systolic blood
Externí odkaz:
https://doaj.org/article/78b10788b725414dbbab332b1f6a1ac1
Autor:
José M. Rodriguez-Valadez, Malak Tahsin, Kirsten E. Fleischmann, Umesh Masharani, Joseph Yeboah, Meyeon Park, Lihua Li, Ellerie Weber, Yan Li, Asem Berkalieva, Wendy Max, M.G. Myriam Hunink, Bart S. Ferket
Publikováno v:
Diabetes Care, 46(6), 1300-1310. American Diabetes Association Inc.
Diabetes Care
Diabetes Care
BACKGROUND Eligibility for glucagon-like peptide 1 receptor agonists (GLP-1RA) and sodium–glucose cotransporter 2 inhibitors (SGLT2i) has been expanded to patients with diabetes at lower cardiovascular risk, but whether treatment benefits differ by
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b39b9ead449ea030b5397d5c9d27527
https://pure.eur.nl/en/publications/d85247f5-eb59-449b-9622-17886569df44
https://pure.eur.nl/en/publications/d85247f5-eb59-449b-9622-17886569df44
